Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [1] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Sharma, Ashish
    Hafeez Faridi, M.
    Kumar, Nilesh
    Parachuri, Nikulaa
    Sharma, Rohini
    Kuppermann, Baruch D.
    Bandello, Francesco
    Loewenstein, Anat
    Regillo, Carl D.
    EYE, 2020, 34 (06) : 1008 - 1009
  • [2] Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
    Ratra, Dhanashree
    Roy, Krishnakanta
    Giridhar, Sneha
    Madaan, Sushant
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (01) : 135 - 149
  • [3] Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
    Dhanashree Ratra
    Krishnakanta Roy
    Sneha Giridhar
    Sushant Madaan
    Ophthalmology and Therapy, 2022, 11 : 135 - 149
  • [4] Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy
    Sharma, Ashish
    Kumar, Nilesh
    Kuppermann, Baruch D.
    JAMA OPHTHALMOLOGY, 2023, 141 (02) : 128 - 129
  • [5] Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
    Soman, Manoj
    Nair, Indu
    Sheth, Jay U.
    Nair, Unnikrishnan
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (03) : 1175 - 1186
  • [6] Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
    Manoj Soman
    Indu Nair
    Jay U. Sheth
    Unnikrishnan Nair
    Ophthalmology and Therapy, 2022, 11 : 1175 - 1186
  • [7] Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
    Guerra Veloz, Maria Fernanda
    Belvis Jimenez, Maria
    Valdes Delgado, Teresa
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    Arguelles-Arias, Federico
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [8] Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
    Debdulal Chakraborty
    Michael W. Stewart
    Jay U. Sheth
    Tushar K. Sinha
    Subhendu Boral
    Arnab Das
    Soumen Mondal
    Angshuman Mukherjee
    Ophthalmology and Therapy, 2021, 10 : 337 - 348
  • [9] Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
    Chakraborty, Debdulal
    Stewart, Michael W.
    Sheth, Jay U.
    Sinha, Tushar K.
    Boral, Subhendu
    Das, Arnab
    Mondal, Soumen
    Mukherjee, Angshuman
    OPHTHALMOLOGY AND THERAPY, 2021, 10 (02) : 337 - 348
  • [10] Using real-world data to evaluate biosimilar switching
    Dutcher, Sarah K.
    Eworuke, Efe
    Blum, Michael D.
    Ball, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (07) : 814 - 816
12345